Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas.

Disease markers - 1 Jan 2018

Sadlecki Pawel, Grzanka Dariusz, Grabiec Marek

Abstract excerpt

The Idylla NRAS Mutation Test, performed on the Biocartis Idylla system, is an in vitro diagnostic tool for the qualitative assessment of 18 NRAS mutations in codons 12, 13, 59, 61, 117, and 146. Low-grade serous ovarian cancer (LGSC) represents less than 10% of all serous ovarian carcinomas. LGSCs are believed to arise from preexisting cystadenomas or serous borderline tumors (SBOTs) that eventually progress to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biomarkers, Tumor
Share to Cystadenocarcinoma, Serous

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Membrane Proteins

Share to Molecular Diagnostic Techniques

Share to Ovarian Neoplasms

Share to Real-Time Polymerase Chain Reaction

Source

Open in PubMed Open full text

Identifiers

PMID: 29682098
DOI: 10.1155/2018/1497879
PMCID: PMC5845515

Genes

NRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas.PMID 29682098Read ↗

KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system.Semantic proximity Read ↗

Molecular diagnosis in type I epithelial ovarian cancer.Semantic proximity Read ↗

Micropapillary Serous Borderline Tumor With Microinvasive Low-Grade Serous Carcinoma of the Tunica Vaginalis Harboring NRAS p.Q61R Mutation: Expanding the Molecular Spectrum of Paratesticular Müllerian-Type Tumors.Semantic proximity Read ↗

Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.Semantic proximity Read ↗

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.Semantic proximity Read ↗

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.Semantic proximity Read ↗

Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.Semantic proximity Read ↗

Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes.Semantic proximity Read ↗

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.Semantic proximity Read ↗

Detection of an NRAS mutation in Erdheim-Chester disease.Semantic proximity Read ↗

Molecular characterization of 103 ovarian serous and mucinous tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.